Drug:
Reaction: NO ADVERSE EVENT
20250101 - 20251231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 25128000 |
US |
||
No adverse event, Product storage error, |
||||
VEDOLIZUMAB, |
||||
| 302 | 25128139 |
US |
66 | |
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 303 | 25128214 |
US |
57 | |
Wrong technique in product usage process, Off label use, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 304 | 25128791 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 305 | 25128984 |
US |
68 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, GABAPENTIN, FOLIC ACID, CELECOXIB, |
||||
| 306 | 25129039 |
US |
61 | |
Device delivery system issue, Product preparation error, No adverse event, |
||||
ALBUTEROL SULFATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 307 | 25129055 |
US |
53 | |
Wrong technique in product usage process, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 308 | 25129140 |
US |
2 | |
Off label use, No adverse event, |
||||
TOCILIZUMAB, TOCILIZUMAB, GABAPENTIN, GLIMEPIRIDE, HYDRALAZINE HYDROCHLORIDE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, METHOTREXATE, METHOTREXATE SODIUM, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOPROLOL TARTRATE, METOPROLOL, PANTOPRAZOLE, PREDNISONE, COLLAGENASE SANTYL, SOTALOL HYDROCHLORIDE, VALSARTAN, VALSARTAN, |
||||
| 309 | 25129210 |
US |
||
Recalled product administered, No adverse event, |
||||
RAMIPRIL, |
||||
| 310 | 25129211 |
US |
||
Product dispensing error, No adverse event, |
||||
POLYETHYLENE GLYCOL-3350 AND ELECTROLYTES, |
||||
| 311 | 25129407 |
US |
73 | 1 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 312 | 25129444 |
US |
43 | 2 |
Product dose omission issue, Device issue, Accidental exposure to product, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, CYCLOSPORINE, CYCLOSPORINE, FAMOTIDINE, CETIRIZINE HYDROCHLORIDE, |
||||
| 313 | 25129834 |
US |
||
No adverse event, Underdose, Off label use, |
||||
| 314 | 25129878 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
| 315 | 25129927 |
US |
7 | 2 |
No adverse event, |
||||
INSULIN LISPRO, |
||||
| 316 | 25130030 |
US |
||
Product dose omission issue, Product use issue, No adverse event, |
||||
PREDNISOLONE ACETATE, |
||||
| 317 | 25130087 |
US |
||
Off label use, No adverse event, |
||||
RITUXIMAB, |
||||
| 318 | 25130518 |
US |
2 | |
No adverse event, Liquid product physical issue, |
||||
VEDOLIZUMAB, |
||||
| 319 | 25130956 |
US |
||
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 320 | 25130962 |
US |
2 | |
No adverse event, Pregnancy, |
||||
| 321 | 25131361 |
US |
63 | 2 |
Off label use, Off label use, No adverse event, |
||||
GANCICLOVIR SODIUM, GANCICLOVIR, GANCICLOVIR SODIUM, GANCICLOVIR, VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR, VALGANCICLOVIR HYDROCHLORIDE POWDER,, VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR, VALGANCICLOVIR HYDROCHLORIDE POWDER,, METHYLPREDNISOLONE, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLIC ACID, MYCOPHENILIC ACID, PREDNISONE, ACYCLOVIR, LEVOFLOXACIN, LEVOFLOXACIN IN 5% DEXTROSE, |
||||
| 322 | 25131786 |
US |
||
Off label use, No adverse event, |
||||
SELINEXOR, |
||||
| 323 | 25131787 |
US |
||
Off label use, No adverse event, |
||||
SELINEXOR, |
||||
| 324 | 25131921 |
US |
||
No adverse event, Product use issue, |
||||
DEXLANSOPRAZOLE, |
||||
| 325 | 25120926 |
US |
28 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 326 | 25121302 |
US |
75 | |
Drug dose omission by device, Wrong technique in product usage process, Off label use, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 327 | 25121327 |
US |
||
Intercepted product storage error, No adverse event, |
||||
RITUXIMAB, PERTUZUMAB, TRASTUZUMAB, BEVACIZUMAB, OMALIZUMAB, OMALIZUMAB, |
||||
| 328 | 25121342 |
US |
2 | |
Product dispensing error, No adverse event, |
||||
ALECTINIB HYDROCHLORIDE, ALLOPURINOL, METOPROLOL TARTRATE, METOPROLOL, ICOSAPENT ETHYL, |
||||
| 329 | 25121392 |
US |
49 | 2 |
Off label use, No adverse event, |
||||
QUERCETIN, QUERCETIN,, AMLODIPINE, TRIAMTERENE AND HYDROCHLOROTHIAZIDE, |
||||
| 330 | 25121504 |
US |
22 | 2 |
Underdose, Device difficult to use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, |
||||
| 331 | 25122191 |
US |
||
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
LEVALBUTEROL TARTRATE, |
||||
| 332 | 25122235 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 333 | 25122248 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 334 | 25122371 |
US |
75 | 2 |
Inappropriate schedule of product administration, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 335 | 25122423 |
US |
11 | 1 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 336 | 25122473 |
US |
1 | |
No adverse event, Product availability issue, |
||||
MESALAMINE, |
||||
| 337 | 25122676 |
US |
55 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 338 | 25123029 |
US |
68 | |
Incorrect dose administered by device, Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, |
||||
| 339 | 25123050 |
US |
||
Therapeutic product effect decreased, No adverse event, Off label use, Product preparation issue, |
||||
| 340 | 25123059 |
US |
2 | |
Product quality issue, Accidental exposure to product, No adverse event, |
||||
| 341 | 25123061 |
US |
61 | |
Wrong technique in product usage process, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, TIOTROPIUM BROMIDE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 342 | 25123079 |
US |
65 | |
Wrong technique in product usage process, Device deposit issue, No adverse event, Device issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 343 | 25123685 |
US |
||
Product storage error, No adverse event, |
||||
OBINUTUZUMAB, |
||||
| 344 | 25123732 |
US |
47 | |
Drug dose omission by device, Product preparation error, Wrong technique in device usage process, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 345 | 25123853 |
US |
||
No adverse event, |
||||
EPHEDRINE SULFATE, |
||||
| 346 | 25123895 |
US |
||
Wrong technique in product usage process, Device deposit issue, Drug dose omission by device, Extra dose administered, Drug ineffective, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 347 | 25123972 |
US |
45 | |
Device delivery system issue, Drug dose omission by device, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 348 | 25123990 |
US |
||
Accidental underdose, No adverse event, |
||||
TOVORAFENIB, |
||||
| 349 | 25123997 |
US |
||
Therapeutic product effect decreased, No adverse event, Off label use, |
||||
| 350 | 25124403 |
US |
||
No adverse event, Product dose omission issue, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 351 | 25124789 |
US |
||
Off label use, No adverse event, Product prescribing error, |
||||
RITUXIMAB, |
||||
| 352 | 25124924 |
US |
40 | 2 |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 353 | 25125082 |
HR |
19 | 2 |
Suicide attempt, Overdose, No adverse event, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 354 | 25125283 |
US |
||
Drug effect less than expected, Intentional underdose, No adverse event, |
||||
FEXOFENADINE HYDROCHLORIDE, |
||||
| 355 | 25125395 |
US |
60 | 1 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 356 | 25125434 |
HR |
84 | 2 |
Suicide attempt, No adverse event, |
||||
AMLODIPINE, |
||||
| 357 | 25125485 |
US |
2 | |
Product dose omission issue, No adverse event, |
||||
| 358 | 25126123 |
US |
1 | |
No adverse event, Product use issue, |
||||
BORTEZOMIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 359 | 25126259 |
US |
6 | |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 360 | 25115618 |
US |
90 | |
Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
LEVALBUTEROL TARTRATE, LEVALBUTEROL TARTRATE, |
||||
| 361 | 25115789 |
US |
2 | |
Syringe issue, Product quality issue, Product dose omission issue, No adverse event, Device defective, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 362 | 25115807 |
US |
14 | 2 |
Product dose omission issue, Drug delivery system malfunction, Device malfunction, Needle issue, No adverse event, |
||||
OMALIZUMAB, |
||||
| 363 | 25115817 |
US |
||
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, |
||||
| 364 | 25115889 |
US |
||
Product packaging quantity issue, No adverse event, |
||||
BALOXAVIR MARBOXIL, |
||||
| 365 | 25116442 |
US |
36 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 366 | 25116446 |
US |
||
Wrong technique in product usage process, Drug dose omission by device, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 367 | 25116473 |
US |
59 | |
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, No adverse event, |
||||
LEVALBUTEROL TARTRATE, LEVALBUTEROL TARTRATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 368 | 25116483 |
US |
29 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
LEVALBUTEROL TARTRATE, |
||||
| 369 | 25116504 |
US |
25 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 370 | 25116531 |
US |
27 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 371 | 25116559 |
US |
||
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 372 | 25116645 |
US |
11 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 373 | 25116646 |
US |
67 | |
Drug dose omission by device, Wrong technique in product usage process, Product use in unapproved indication, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 374 | 25116667 |
US |
66 | |
Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 375 | 25116705 |
US |
||
No adverse event, Drug ineffective for unapproved indication, Off label use, |
||||
| 376 | 25116712 |
US |
||
No adverse event, Drug ineffective for unapproved indication, Underdose, Off label use, |
||||
| 377 | 25116780 |
US |
79 | 2 |
No adverse event, |
||||
ABEMACICLIB, |
||||
| 378 | 25116867 |
US |
20 | 1 |
Accidental exposure to product, Underdose, Needle issue, Device malfunction, No adverse event, |
||||
OMALIZUMAB, |
||||
| 379 | 25116915 |
US |
||
Device delivery system issue, Incorrect dose administered by device, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 380 | 25117231 |
US |
||
Lacrimation increased, Malaise, Affect lability, Pain, Oropharyngeal pain, Headache, No adverse event, Off label use, |
||||
| 381 | 25117232 |
US |
||
No adverse event, Off label use, |
||||
| 382 | 25117255 |
US |
1 | |
Product storage error, No adverse event, |
||||
| 383 | 25117263 |
US |
20 | 2 |
Product distribution issue, No adverse event, |
||||
OMALIZUMAB, |
||||
| 384 | 25117281 |
US |
||
No adverse event, |
||||
DAPAGLIFLOZIN, |
||||
| 385 | 25117451 |
US |
66 | |
Drug dose omission by device, Device deposit issue, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 386 | 25117805 |
US |
||
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 387 | 25117865 |
US |
70 | |
Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 388 | 25117880 |
US |
||
Off label use, Off label use, No adverse event, |
||||
| 389 | 25117899 |
US |
||
Dacryocystitis, Mass, No adverse event, |
||||
| 390 | 25118017 |
US |
45 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 391 | 25118021 |
US |
57 | 1 |
Product storage error, Wrong technique in device usage process, Needle issue, No adverse event, |
||||
OMALIZUMAB, LEVOTHYROXINE, APIXABAN, APIXABAN, |
||||
| 392 | 25118136 |
US |
||
Wrong technique in product usage process, Device issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 393 | 25118159 |
US |
62 | |
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 394 | 25118217 |
US |
54 | |
Wrong technique in product usage process, Circumstance or information capable of leading to device use error, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 395 | 25118399 |
HR |
19 | 2 |
Suicide attempt, No adverse event, Overdose, |
||||
ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, |
||||
| 396 | 25118529 |
US |
16 | 1 |
Device malfunction, Accidental exposure to product, No adverse event, Underdose, |
||||
OMALIZUMAB, |
||||
| 397 | 25118675 |
US |
72 | 2 |
Accidental exposure to product, Product complaint, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, ACYCLOVIR, ACYCLOVIR, ALBUTEROL SULFATE, ALBUTEROL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CLONAZEPAM, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, GABAPENTIN, LEVOTHYROXINE, LINACLOTIDE, LINACLOTIDE, SERTRALINE, SERTRALINE, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, |
||||
| 398 | 25118716 |
US |
1 | |
No adverse event, Incorrect product administration duration, Wrong technique in product usage process, |
||||
BUDESONIDE, BUDESONIDE, |
||||
| 399 | 25118759 |
US |
||
Product storage error, No adverse event, |
||||
| 400 | 25118838 |
US |
19 | 2 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28